menu
    • menu
    [{"orgOrder":0,"company":"Se-cure Pharmaceuticals","sponsor":"Clalit","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Femarelle","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Se-cure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Se-cure Pharmaceuticals \/ Clalit","highestDevelopmentStatusID":"1","companyTruncated":"Se-cure Pharmaceuticals \/ Clalit"},{"orgOrder":0,"company":"Se-cure Pharmaceuticals","sponsor":"Se-cure Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Femarelle","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Se-cure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Se-cure Pharmaceuticals \/ Se-cure Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Se-cure Pharmaceuticals \/ Se-cure Pharmaceuticals"},{"orgOrder":0,"company":"Se-cure Pharmaceuticals","sponsor":"Clalit","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ISRAEL","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Brizo","moa":"Undisclosed","graph1":"Urology","graph2":"Undisclosed","graph3":"Se-cure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Se-cure Pharmaceuticals \/ Clalit","highestDevelopmentStatusID":"1","companyTruncated":"Se-cure Pharmaceuticals \/ Clalit"}]

    Find Clinical Drug Pipeline Developments & Deals by Se-cure Pharmaceuticals

    Menu

    Se-cure Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brizo

                            Therapeutic Area : Urology

                            Study Phase : Undisclosed

                            Sponsor : Clalit

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)

                            Details : Brizo is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 07, 2022

                            Lead Product(s) : Brizo

                            Therapeutic Area : Urology

                            Highest Development Status : Undisclosed

                            Sponsor : Clalit

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Femarelle

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Recipient : Dr. Lila Nachtigall Rapid Medical Research, New York

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal...

                            Details : Femarelle is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Atrophic Vaginitis.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 30, 2011

                            Lead Product(s) : Femarelle

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Recipient : Dr. Lila Nachtigall Rapid Medical Research, New York

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Se-cure Pharmaceuticals

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Femarelle

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Clalit

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms

                            Details : Femarelle is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 05, 2010

                            Lead Product(s) : Femarelle

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Clalit

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth